ArticleInternational journal of rheumatology2011
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence.
Article in International journal of rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.Arthritis research & therapy · 2016Trial
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease.Mediterranean journal of rheumatology · 2022Review
- Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase.Frontiers in immunology · 2022Article
- Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells.Frontiers in immunology · 2022Review
- Upcoming treatments for morphea.Immunity, inflammation and disease · 2021Review
- Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease.ACR open rheumatology · 2021Article
- Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?International journal of molecular sciences · 2019Review
- Biologic Treatments in Interstitial Lung Diseases.Frontiers in medicine · 2019Review
- Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges.Clinical & translational immunology · 2019Review
- [American journal of nuclear medicine and molecular imaging · 2019Article
- Dkk1: A key molecule in joint remodelling and fibrosis.Mediterranean journal of rheumatology · 2017Review
- Systemic Sclerosis and Malignancy: A Review of Current Data.Journal of clinical medicine research · 2016Review
- Fibrogenesis, novel lessons from animal models.Seminars in immunopathology · 2015Review
- Article
- [Established medications : new areas of application].Zeitschrift fur Rheumatologie · 2013Review
- Biologic therapy for autoimmune diseases: an update.BMC medicine · 2013Review
- Rituximab-induced regression of CREST-related calcinosis.Clinical rheumatology · 2013Article
- L-selectin and skin damage in systemic sclerosis.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence from animal models suggests that B-cells may be actively involved in the fibrotic process. B-cells from tight skin mice, an animal model of scleroderma, display a "hyperresponsive" phenotype; treatment with rituximab (RTX) significantly attenuates skin fibrosis in this animal model. In humans, B-cell infiltration is a prominent finding in most lung biopsies obtained from patients with SSc-associated interstitial lung disease. Several open label studies have assessed the clinical efficacy of RTX in SSc. In most patients skin fibrosis improved; lung function either improved or remained stable. Definite conclusions regarding the clinical efficacy of RTX in SSc cannot be drawn but further exploration with a multicenter, randomized study is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.